Shares of Zydus Lifesciences Limited were trading in the green on 30 July after the company announced entering into agreements with PAI and two minority shareholders of Amplitude Surgical to acquire blocks of shares representing 85.6% stake of Amplitude Surgical’s share capital and voting rights for €6.25 per share and a total consideration of €256.8 million. 

Zydus now owns 85.6% of Amplitude Surgical’s share capital and voting rights after all conditions prior to completion were met and the Block Acquisition was completed on 29 July 2025.  

Olivier Jallabert will continue to serve as CEO of Amplitude Surgical and has invested in the company that has completed the Block Acquisition.

In the framework of the Block Acquisition, Amplitude Surgical has terminated its 19 June 2018 liquidity contract with Oddo BHF and Natixis, effective 28 July 2025.

On 30 July 2025, Zydus will file a simplified mandatory tender offer for all of Amplitude Surgical’s remaining outstanding shares at a price of €6.25 per share, the same as the price paid for the Block Acquisition.  

Given the undertakings to tender received from seven shareholders representing 4.7% of share capital and voting rights, Zydus will be able to secure more than 90% of Amplitude Surgical’s capital and voting rights upon completion of the Offer and will then request the implementation of a squeeze-out.

Subject to the French Financial Market Authority’s (Autorité des marches financiers, AMF) approval, the Offer is expected to be opened in September 2025. No additional regulatory approvals will be required.  

On 28 July 2025, Amplitude Surgical’s Board of Directors unanimously welcomed the Offer and issued a reasoned judgment on the same day, after receipt of the fairness opinion from Finexsi, the Offer’s independent expert.

Zydus Lifesciences Ltd., with the overriding goal of providing people with the freedom to live healthier and more fulfilling lives, is an innovative, worldwide lifesciences company that discovers, develops, produces, and markets a wide range of healthcare solutions.  The company employs over 27,000 people worldwide, including 1,400 R&D scientists, and is motivated by its purpose to open up new possibilities in life sciences through high-quality healthcare solutions that change people’s lives.

At 1:10 pm, the shares of Zydus Lifesciences were trading 0.11% higher at Rs 996 on NSE.

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!